In vitro activity of meropenem-vaborbactam plus aztreonam against metallo-ß-lactamase-producing Klebsiella pneumoniae.
Antimicrob Agents Chemother
; 68(4): e0134623, 2024 Apr 03.
Article
in En
| MEDLINE
| ID: mdl-38426743
ABSTRACT
We evaluated the in vitro activity of meropenem-vaborbactam plus aztreonam (MEV-ATM) against 140 metallo-ß-lactamase (MBL)-producing Klebsiella pneumoniae isolates. Among them, 25 isolates (17.9%) displayed minimum inhibitory concentrations (MIC) ≥ 8 µg/mL, while 112 (80.0%) had MIC ≤ 2 µg/mL. Genomic analysis and subsequent gene cloning experiments revealed OmpK36 134-135GD-insertion and increased carbapenemase gene (blaNDM-1 and blaOXA-48-like) copy numbers are the main factors responsible for MEV-ATM non-susceptibility. Notably, MEV-ATM is actively against aztreonam-avibactam-resistant mutants due to CMY-16 mutations.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Boronic Acids
/
Aztreonam
/
Anti-Bacterial Agents
Language:
En
Journal:
Antimicrob Agents Chemother
Year:
2024
Type:
Article
Affiliation country:
United States